Fractyl Health swings to Q1 FY26 profit of $9.2 million; adjusted EBITDA loss narrows to $18 million

Fractyl Health

Fractyl Health

GUTS

0.00
  • Fractyl Health posted net income of USD 9.2 million for quarter ended March 31, 2026, swinging from a net loss of USD 23.7 million a year earlier on a USD 30.1 million non-cash fair-value change tied to warrant liabilities.
  • R&D expense fell 19.59% to USD 15.6 million, while SG&A expense was essentially flat at USD 5.2 million.
  • Adjusted EBITDA loss narrowed to USD 18 million from USD 23 million a year earlier; cash and cash equivalents totaled USD 63.2 million, with runway guided into early 2027.
  • Next Revita clinical readouts include 1-year REVEAL-1 Cohort data in Q2 2026, 1-year randomized REMAIN-1 Midpoint Cohort data in Q3 2026, then topline 6-month randomized REMAIN-1 Pivotal Cohort data in early Q4 2026.
  • Late Q4 2026 timing reaffirmed for potential FDA De Novo marketing application submission in post-GLP-1 weight maintenance; RJVA-001 first-in-human dosing anticipated in second half of 2026 following Netherlands CTA authorization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-219365), on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.